Ecopetrol
EC
Apple
AAPL
D.R. Horton
DHI
4
Meritage Homes
MTH
5
Lennar Corp
LEN
US Stock MarketDetailed Quotes
CLDX Celldex Therapeutics
- 18.150
- -1.780-8.93%
Close Mar 31 16:00 ET
- 18.140
- -0.010-0.06%
Pre 05:32 ET
1.20BMarket Cap-7.41P/E (TTM)
19.840High17.630Low1.29MVolume19.750Open19.930Pre Close23.47MTurnover2.12%Turnover RatioLossP/E (Static)66.38MShares47.00052wk High1.61P/B1.11BFloat Cap17.63052wk Low--Dividend TTM61.14MShs Float3374.997Historical High--Div YieldTTM11.09%Amplitude1.500Historical Low18.136Avg Price1Lot Size
About Celldex Therapeutics Company
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
Company Profile
SymbolCLDX
Company NameCelldex Therapeutics
Listing DateMay 1, 1986
Founded1983
CEOMr. Anthony S. Marucci
MarketNASDAQ
Employees186
Fiscal Year Ends12-31
AddressPerryville III Building,53 Frontage Road,Suite 220
CityHampton
ProvinceNew Jersey
CountryUnited States of America
Zip Code08827
Phone1-908-454-7120
Websitehttp://www.celldex.com
Company Executives
- Name
- Position
- Salary
- Anthony S. Marucci
- Director, President and Chief Executive Officer
- 8.36M
- Elizabeth Crowley
- Senior Vice President and Chief Product Development Officer
- --
- Richard M. Wright, PhD
- Senior Vice President and Chief Commercial Officer
- --
- Dr. Tibor Keler, PhD
- Executive Vice President and Chief Scientific Officer
- 3.42M
- Dr. Ronald A. Pepin, PhD
- Senior Vice President and Chief Business Officer
- --
- Dr. Diane C. Young, M.D.
- Senior Vice President and Chief Medical Officer
- 2.97M
- Sam Martin
- Treasurer, Senior Vice President, Secretary, Principal Accounting Officer and Chief Financial Officer
- 2.95M
- Sarah Cavanaugh
- Senior Vice President, Corporate Affairs and Administration
- --
- Freddy A. Jimenez
- Senior Vice President and General Counsel
- --
- Dr. Margo Heath-Chiozzi, M.D.
- Senior Vice President, Regulatory Affairs
- 2.94M
- Karen L. Shoos
- Chairman of the Board
- 385.77K
- Herbert J. Conrad
- Independent Director
- 364.94K
- Cheryl L. Cohen
- Independent Director
- 367.02K
- Keith L. Brownlie
- Independent Director
- 373.27K
- Herbert J. Conrad
- Independent Director
- --
- Harry H. Penner, Jr
- Independent Director
- 371.19K
- Dr. Rita I. Jain, M.D.
- Independent Director
- 599.50K
- Dr. James J. Marino, J.D.
- Independent Director
- 377.44K
- Dr. Garry A. Neil, M.D.
- Independent Director
- 366.22K
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings